The 5th Annual Stomp Out Cancer event in honor of Dan Hund and his battle with a one in a million cancer, adrenocortical cancer. Consider filling out a bracket for March madness which starts at noon eastern Thursday 3/20/25 and win Dan’s shoes size 12! shorturl.at/NZ6ei

Two recent co-publications with my incredible wife (and gyn-onc) IsabelBeshar. A case report on a patient with vaginal cancer and sustained response to EVP, and our dear sweet August. Our hearts are full

🚨 Proud to share our recent paper on virtual second opinions for cancer care Stanford Cancer Institute. Changes in management were recommended in >50% of cases. Many of these opinions were associated with: 1. de-escalation of care - e.g NOT recommending adjuvant chemotherapy for

1/ Huge thanks to all collaborators, but especially to Alex Chehrazi-Raffle, MD , great friend and mentor, for the opportunity to contribute to this multicenter study on HDCT in refractory/recurrent #GCT!

Great discussion here with Mark Cuban. Many of my patients with prostate cancer have been faced with the decision of forgoing the optimal treatment for their cancer or selling their car or home to afford treatment. Mark’s pharmacy then came along and brought down the out-of-pocket

Comprehensive summary of management of testicular cancers 💯 Important areas of discovery in next 10 years include novel therapeutic approaches (CLDN6, HMAs, MDM2) and de-escalation of therapy

.Clifford Hudis at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever➡️brnw.ch/21wT3U4

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

Dr. Samer Srour presents updated results from the TRAVERSE study at #ASCO25. A single infusion of allogeneic CD70 CAR T-cell therapy ALLO-316 showed manageable safety and encouraging responses in heavily pretreated advanced ccRCC. #EndCancer

Excellent Germ Cell Tumor session today at ASCO #TCSM led by DrBagrodia featuring Drs. Einhorn, Lucia Nappi, and Haugnes. Appreciate the practical data and common pitfalls (don't fret a mild AFP, high NPV for PET in seminoma, consider RPLND in stage II sem)